ADMA Biologics Inc

Common Name

ADMA Biologics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

685

Ticker

ADMA

Exchange

NASDAQ/NMS

Website

www.admabiologics.com

Description

Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious ... Show more

Financial Statements of ADMA Biologics

Below are the financial statements of ADMA Biologics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	103.15^a	51.35^a
Accounts receivable, net	50^a	27.42^a
Inventories	170.24^a	172.91^a
Prepaid expenses and other current assets	8.03^a	5.33^a
Total current assets	331.41^a	257.01^a
Assets	—	—
Property and equipment, net	54.71^a	53.84^a
Intangible assets, net	0.46^a	0.5^a
Goodwill	3.53^a	3.53^a
Deferred tax assets, net	84.28^a	0^a
Right-of-use assets	8.63^a	9.64^a
Deposits and other assets	5.66^a	4.67^a
Total assets	488.68^a	329.18^a
Current liabilities	—	—
Accounts payable	20.22^a	15.66^a
Accrued expenses and other current liabilities	33.96^a	32.92^a
Current portion of deferred revenue	0.14^a	0.18^a
Current portion of lease obligations	1.22^a	1.05^a
Total current liabilities	55.54^a	49.81^a
Liabilities and stockholders’ equity	—	—
Senior notes payable, net of discount	72.34^a	130.59^a
Deferred revenue, net of current portion	1.55^a	1.69^a
End of term fee	1.31^a	1.69^a
Lease obligations, net of current portion	8.56^a	9.78^a
Other non-current liabilities	0.36^a	0.42^a
Total liabilities	139.66^a	193.98^a
Stockholders’ equity	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0^a	0^a
Common stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023	0.02^a	0.02^a
Additional paid-in capital	657.58^a	641.44^a
Accumulated deficit	-308.58^a	-506.26^a
Total stockholders’ equity	349.02^a	135.21^a
Total liabilities and stockholders’ equity	488.68^a	329.18^a

Verified Sources Behind ADMA Biologics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore ADMA Biologics’s data sources below and access millions more through our Disclosure Search.

a. ADMA Biologics's 10-K 2024

Trace every data point back to ADMA Biologics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

ADMA Biologics Inc

Financial Statements of ADMA Biologics

Verified Sources Behind ADMA Biologics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

ACADIA Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Blueprint Medicines Corp

Insmed Inc

Ultragenyx Pharmaceutical Inc

BridgeBio Pharma Inc